Moderna's anti-Covid vaccine has also shown efficacy on adolescents: no cases of Covid-19 have been observed after the two doses of vaccine, consistent with a vaccine efficacy of 100%, and vaccine efficacy was observed equal to 93% after the first dose.
This was revealed by the data announced today by Moderna relating to the TeenCOVE study on adolescents.
"We are motivated by the fact that mRNA has been highly effective in preventing Covid-19 in adolescents - said Stéphane Bancel, CEO of Moderna -. We will send these results to the FDA and other regulatory bodies in early June, asking for authorization. ".
Moderna announced today that the TeenCOVE study of its COVID-19 vaccine for teens reaches its primary goal, and the company therefore plans to submit the data to regulatory authorities in early June.
The primary immunogenicity goal of no less than that of the adult comparison group of the Phase 3 study was achieved, Moderna explains in a note. , "consistent with a vaccine efficacy of 100%". And "using the Center for Disease Control and Prevention (CDC) case definition, 93% vaccine efficacy was observed after the first dose. No significant safety concerns were reported."
The company plans to submit the data to regulatory agencies globally in early June. The TeenCOVE study enrolled more than 3,700 participants between the ages of 12 and 18 in the United States.
"We are motivated by the fact that mRNA-1273 has been highly effective in preventing COVID-19 in adolescents. It is particularly exciting to see that the Moderna COVID-19 vaccine can prevent Sars-Cov-2 infection," said Stéphane. Bancel, CEO of Moderna - We will be sending these results to the US FDA and other global regulators in early June, seeking permission.
We continue to be committed to our work to help end the COVID-19 pandemic. " . (HANDLE).
